Pitcairn Co. Has $372,000 Holdings in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)

Pitcairn Co. trimmed its position in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) by 7.9% during the first quarter, Holdings Channel.com reports. The firm owned 7,957 shares of the biopharmaceutical company’s stock after selling 679 shares during the period. Pitcairn Co.’s holdings in Ultragenyx Pharmaceutical were worth $372,000 as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. Headlands Technologies LLC acquired a new position in shares of Ultragenyx Pharmaceutical during the first quarter worth approximately $28,000. UMB Bank n.a. raised its position in shares of Ultragenyx Pharmaceutical by 118.8% during the fourth quarter. UMB Bank n.a. now owns 606 shares of the biopharmaceutical company’s stock worth $29,000 after purchasing an additional 329 shares during the period. GAMMA Investing LLC raised its position in shares of Ultragenyx Pharmaceutical by 622.3% during the first quarter. GAMMA Investing LLC now owns 1,004 shares of the biopharmaceutical company’s stock worth $47,000 after purchasing an additional 865 shares during the period. Van ECK Associates Corp raised its position in shares of Ultragenyx Pharmaceutical by 34.0% during the fourth quarter. Van ECK Associates Corp now owns 1,578 shares of the biopharmaceutical company’s stock worth $75,000 after purchasing an additional 400 shares during the period. Finally, International Assets Investment Management LLC raised its position in shares of Ultragenyx Pharmaceutical by 3,182.4% during the fourth quarter. International Assets Investment Management LLC now owns 1,674 shares of the biopharmaceutical company’s stock worth $80,000 after purchasing an additional 1,623 shares during the period. 97.67% of the stock is owned by institutional investors and hedge funds.

Ultragenyx Pharmaceutical Stock Down 0.1 %

RARE traded down $0.05 during trading on Thursday, reaching $45.06. 737,859 shares of the company were exchanged, compared to its average volume of 809,375. The company’s 50-day moving average is $41.37 and its two-hundred day moving average is $44.53. The company has a market cap of $3.75 billion, a price-to-earnings ratio of -5.80 and a beta of 0.56. Ultragenyx Pharmaceutical Inc. has a 12-month low of $31.52 and a 12-month high of $54.56.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last released its quarterly earnings results on Thursday, May 2nd. The biopharmaceutical company reported ($2.03) earnings per share for the quarter, missing the consensus estimate of ($1.72) by ($0.31). Ultragenyx Pharmaceutical had a negative net margin of 138.58% and a negative return on equity of 425.63%. The business had revenue of $108.83 million during the quarter, compared to analysts’ expectations of $116.03 million. During the same period in the previous year, the business earned ($2.33) EPS. The business’s revenue was up 8.3% on a year-over-year basis. Equities analysts forecast that Ultragenyx Pharmaceutical Inc. will post -6.45 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on RARE shares. Robert W. Baird upped their price target on Ultragenyx Pharmaceutical from $68.00 to $72.00 and gave the stock an “outperform” rating in a report on Friday, May 31st. The Goldman Sachs Group upgraded Ultragenyx Pharmaceutical from a “neutral” rating to a “buy” rating and upped their price objective for the company from $56.00 to $67.00 in a research note on Thursday, June 6th. Wedbush restated a “neutral” rating and issued a $45.00 price objective on shares of Ultragenyx Pharmaceutical in a research note on Thursday, July 18th. Bank of America reduced their price objective on Ultragenyx Pharmaceutical from $83.00 to $76.00 and set a “buy” rating for the company in a research note on Friday, May 31st. Finally, Cantor Fitzgerald reiterated an “overweight” rating and set a $115.00 price target on shares of Ultragenyx Pharmaceutical in a research note on Monday. Two equities research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $86.50.

Insider Buying and Selling at Ultragenyx Pharmaceutical

In other Ultragenyx Pharmaceutical news, EVP Karah Herdman Parschauer sold 9,806 shares of the firm’s stock in a transaction dated Wednesday, June 12th. The stock was sold at an average price of $45.00, for a total value of $441,270.00. Following the sale, the executive vice president now owns 57,981 shares of the company’s stock, valued at approximately $2,609,145. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In other news, EVP Karah Herdman Parschauer sold 9,806 shares of the stock in a transaction dated Wednesday, June 12th. The stock was sold at an average price of $45.00, for a total transaction of $441,270.00. Following the transaction, the executive vice president now directly owns 57,981 shares in the company, valued at approximately $2,609,145. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Corazon (Corsee) D. Sanders sold 1,737 shares of the stock in a transaction dated Monday, June 10th. The shares were sold at an average price of $41.10, for a total value of $71,390.70. Following the transaction, the director now owns 7,248 shares in the company, valued at $297,892.80. The disclosure for this sale can be found here. Insiders have sold a total of 12,127 shares of company stock valued at $536,593 in the last 90 days. Corporate insiders own 5.80% of the company’s stock.

Ultragenyx Pharmaceutical Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.